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Systematic review
Cochrane Review highlights the need for more targeted research 
on the tolerability of malaria chemoprophylaxis in travellers
The recent Cochrane Collaboration review by Jacquerioz 
and Croft on drugs to prevent malaria in travellers is 
a welcome evaluation of randomised controlled trials 
of malaria chemoprophylaxis in non-immune individu-
als. The goal of the systematic review was to evaluate 
the effi cacy, safety and tolerability of atovaquone-
proguanil, doxycycline and mefl oquine (the three pri-
ority regimens for malaria prophylaxis) compared with 
each other, with the defunct combination chloroquine-
proguanil and with primaquine (considered in some 
countries to be a candidate for chemoprophylaxis of 
travellers’ malaria).
This systematic review is particularly valuable for the 
fact that the stringent selection process meant that only 
scientifi cally rigorous trials were included. The authors 
used appropriate search terms and strategies in screening 
the chosen databases (the Cochrane Infectious Diseases 
Group Specialised Register, the Cochrane Central Register 
of Controlled Trials, the Cochrane Library, Medline, 
Embase, Lilacs, Biosis and the metaRegister of Controlled 
Trials). They also contacted malaria drug experts and 
pharmaceutical companies and hand-searched confer-
ence  proceedings.
The authors did not fi nd suffi cient evidence to allow 
a comparison of the effi cacy of the drugs, and so their 
focus narrowed to the tolerability of antimalarials used 
in chemoprophylaxis. For the evaluation of tolerability, 
primaquine was dropped from the comparators, again 
because of insuffi cient evidence. The systematic review 
could, in essence, be renamed as a systematic review on 
the tolerability of currently used drugs for preventing 
malaria in travellers.
Despite the rigorous and appropriate searches, only 
eight trials (with a total of 4240 randomised participants, 
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including 1098 soldiers) met the inclusion criteria. No 
serious adverse events occurred in any of the included 
studies. This fact should have been highlighted in the 
abstract. The authors concluded there is little quality 
evidence on the tolerability of antimalarial drugs, that 
atovaquone-proguanil and doxycycline are best tolerated 
and that mefl oquine has more adverse effects than other 
regimens (with the exception of chloroquine-proguanil). 
These core fi ndings of the review, together with the data 
presented on moods, mirror exactly the fi ndings of the 
four-arm double-blind study of malaria chemoprophy-
laxis published in 2003.1 Jacquerioz and Croft are to be 
commended for the scientifi c rigour applied to the selec-
tion of studies included in the review, but this rigour is 
lost when they report on their search for case reports of 
deaths in the literature. The authors found case reports of 
22 deaths “associated with mefl oquine,” but they do not 
put these cases into context. They fail to indicate the num-
ber of mefl oquine users (as denominator data), which is 
estimated to be well in excess of 35 million, which would 
make mefl oquine a very safe drug indeed! They do not 
indicate how many lives were saved, in terms of malaria 
cases prevented, by the use of mefl oquine prophylaxis 
for high-risk malaria endemic areas. Furthermore, they 
do not cite an International Society of Travel Medicine 
congress abstract2 presenting a database analysis of sui-
cide that showed no excess of suicide in mefl oquine users 
compared with high background incidence in male popu-
lations worldwide.
The review should have focused exclusively on con-
trolled clinical studies. If case report data are used and 
these tend to be sensational and anecdotal, then powerful 
record linkage analyses also need to be cited, as these 
provide an evidence-based analysis. Two such analyses 
were not unduly negative for mefl oquine users.3 4 The sec-
tions at the beginning of the article showing registration 
details of drugs are more appropriate as appendices and 
detract from the core review.
The authors rightly call for more malaria chemo-
prophylaxis trials with a focus on non-immune travel-
lers and an emphasis on women and children rather than 
soldiers, and they raise the subject of bias. Gender aspects 
are assuming great importance,5 and the excess poor tol-
erability of mefl oquine in women warrants further eval-
uation. Prospective controlled studies are complex and 
expensive and require fi nancial support, but a multiarm 
study can still be independent if research grants are pro-
vided and an academic institution assumes the role of 
sponsor rather than the drug companies. Innovative use 
of record linkage databases can evaluate research ques-
tions without bias. Ultimately the common goal is to pro-
vide accurate data to travel medicine practitioners so that 
malaria chemoprophylaxis guidelines are based on evi-
dence rather than anecdote.
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